Enanta Pharmaceuticals, Inc.
ENTA
$8.53
-$0.12-1.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -92.01M | -96.42M | -104.93M | -116.05M | -115.33M |
| Total Depreciation and Amortization | 3.78M | 3.17M | 2.58M | 2.34M | 2.53M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.36M | 23.70M | 23.14M | 27.82M | 18.66M |
| Change in Net Operating Assets | 43.69M | 14.08M | 8.63M | 7.13M | 4.17M |
| Cash from Operations | -23.18M | -55.46M | -70.58M | -78.76M | -89.97M |
| Capital Expenditure | -20.39M | -26.78M | -25.91M | -17.95M | -10.37M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 77.51M | 104.04M | 166.16M | 76.18M | 61.36M |
| Cash from Investing | 57.12M | 77.26M | 140.26M | 58.24M | 51.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 162.00K | 190.00K | 241.00K | 147.00K | 79.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -25.67M | -25.93M | -25.50M | -27.77M | -20.51M |
| Cash from Financing | -25.51M | -25.74M | -25.26M | -27.63M | -20.43M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.43M | -3.94M | 44.42M | -48.16M | -59.40M |